Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer

被引：0

作者：

Xu, R. ^{[1
]}

Yuhong, L. ^{[1
]}

Huiyan, L. ^{[1
]}

Wei, W. ^{[2
]}

Zhiqiang, W. ^{[1
]}

Xia, Y. ^{[3
]}

Dong, M. ^{[4
]}

Hua, W. Feng ^{[1
]}

Dongsheng, Z. ^{[1
]}

Daren, L. ^{[5
]}

Chen, L. Yin ^{[6
]}

Jun, J. ^{[7
]}

Hua, H. Xiao ^{[8
]}

Wen, P. Jie ^{[9
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Med Oncol, Guangzhou 510275, Guangdong, Peoples R China

[2] First Peoples Hosp Foshan, Med Oncol, Foshan, Peoples R China

[3] Huizhou Cent Hosp, Med Oncol, Huizhou, Peoples R China

[4] Guangdong Gen Hosp, Med Oncol, Guangzhou, Guangdong, Peoples R China

[5] Jiangmen Cent Hosp, Med Oncol, Jiangmen, Peoples R China

[6] Shantou Univ, Coll Med, Canc Hosp, Med Oncol, Shantou, Peoples R China

[7] Dongguan Peoples Hosp, Med Oncol, Dongguan, Peoples R China

[8] Guangxi Med Univ, Tumor Hosp, Med Oncol, Nanning, Peoples R China

[9] Zhongshan Peoples Hosp, Med Oncol, Zhongshan, Peoples R China

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31049-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2127

引用

页码：S373 / S374

页数：2

共 50 条

[1] Continuing single-agent capecitabin as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer
Xu, Rui-hua
Li, Yu-hong
Luo, Huiyan
Wang, Wei
Wang, Zhiqiang
Yuan, Xia
Wang, Fenghua
Zhang, Dong-sheng
Ma, Dong
Lin, Da Ren
Jia, Jun
Hu, Xiao-hua
Peng, Jie Wen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of mCRC
Xu, R.
Li, Y.
Luo, H.
Wang, W.
Wang, Z.
Yuan, X.
Ma, D.
Wang, F. H.
Zhang, D.
Lin, D. R.
Jia, J.
Hu, X. H.
Peng, J. W.
Lin, Y. C.
ANNALS OF ONCOLOGY, 2015, 26 : 43 - 43
[3] Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
Diaz-Rubio, Eduardo
ONCOLOGIST, 2012, 17 (11): : 1426 - 1428
[4] Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety
Luo, H. Y.
Li, Y. H.
Wang, W.
Wang, Z. Q.
Yuan, X.
Ma, D.
Wang, F. H.
Zhang, D. S.
Lin, D. R.
Lin, Y. C.
Jia, J.
Hu, X. H.
Peng, J. W.
Xu, R. H.
ANNALS OF ONCOLOGY, 2016, 27 (06) : 1074 - 1081
[5] SINGLE-AGENT CAPECITABINE AS FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
Davidov, Deyan
JOURNAL OF IMAB, 2009, 15 (01): : 46 - 49
[6] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
Grothey, Axel
NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01): : 10 - 11
[7] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
Axel Grothey
Nature Clinical Practice Oncology, 2009, 6 : 10 - 11
[8] XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
Gerardo Rosati
Antonio Avallone
Giuseppe Aprile
Alfredo Butera
Giorgio Reggiardo
Domenico Bilancia
Cancer Chemotherapy and Pharmacology, 2013, 71 : 257 - 264
[9] XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
Rosati, Gerardo
Avallone, Antonio
Aprile, Giuseppe
Butera, Alfredo
Reggiardo, Giorgio
Bilancia, Domenico
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 257 - 264
[10] High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
Ychou, M
Raoul, JL
Desseigne, F
Borel, C
Caroli-Bosc, FX
Jacob, JH
Seitz, JF
Kramar, A
Hua, A
Lefebvre, P
Couteau, C
Merrouche, Y
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (05) : 383 - 391

← 1 2 3 4 5 →